Confirmed objective response rate (ORR) with ENHERTU plus pertuzumab was 85.1% versus 78. ... the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh ...

Trastuzumab deruxtecan belongs to a group of antineoplastic drugs known as antibody-drug conjugates (ADCs). This type of treatment combines two therapies into one.

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease ...

WILMINGTON, Del., May 07, 2025--(BUSINESS WIRE)--Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel ...

Confirmed objective response rate (ORR) with ENHERTU plus pertuzumab was ... the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new ...

--(BUSINESS WIRE)-- Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically significant ...